protocolSection identificationModule nctId: NCT06297954, orgStudyIdInfo id: GA22-00011, briefTitle: Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-16, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Universidad Autonoma de Nuevo Leon, class: OTHER, descriptionModule briefSummary: A prospective, randomized, double-blind study will be conducted, including all patients with upper gastrointestinal bleeding, defined as vomiting blood or black bowel movements, within 12 hours prior to admission. Patients will be randomized to receive intravenous metoclopramide 20 mg or placebo, a placebo is a look-alike substance that contains no active drug. Then endoscopy will be performed in the following 120 minutes, evaluating endoscopic visualization with the modified Avgerinos scale., conditionsModule conditions: Upper Gastrointestinal Bleeding, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients will be randomized to receive metoclopramide 20 mg IV or placebo, this randomization will be performed by means of a computer sequence to receive each of the treatment sequences. The sequence of treatment (metoclopramide) and placebo in which they will be distributed to patients will be determined using randomization software. A folio number will be assigned and depending on the sequence the treatment or placebo will be administered. Subsequently, the upper endoscopy will be performed in the following 120 minutes, and the endoscopic visualization will be evaluated by the physician performing the procedure by means of the modified Avgerinos scale, primaryPurpose: DIAGNOSTIC, maskingInfo masking: DOUBLE, maskingDescription: As it is double-blind, both physician and patient will not know the treatment they are receiving and it will only be revealed later at the end of the protocol. Following the previous folios, both the treatment and the placebo will be distributed in boxes by default by the research staff, delivering them to the personnel who will apply the drug or placebo, indicating the doses and frequencies of these when administered., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Metoclopramide, interventions name: Placebo, outcomesModule primaryOutcomes measure: To determine the usefulness of metoclopramide in improving endoscopic visualisation in patients with upper gastrointestinal bleeding., secondaryOutcomes measure: To determine whether the use of metoclopramide avoids repeating the endoscopic procedure., secondaryOutcomes measure: To determine whether the use of metoclopramide shortens the length of hospital stay., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Universitario Dr. José Eleuterio González, UANL, status: RECRUITING, city: Monterrey, state: Nuevo León, zip: 64460, country: Mexico, contacts name: José Luis Herrera Elizondo, Physician, role: CONTACT, phone: +528180182968, email: here_herrera_11@hotmail.com, contacts name: José Alberto González González, Physician, role: CONTACT, phone: +528183668061, email: jalbertogastro@gmail.com, geoPoint lat: 25.67507, lon: -100.31847, hasResults: False